ICICI Securities Maintains Hold Rating on Sudeep Pharma, Sets Rs 1,100 Target
ICICI Securities’ research report says Sudeep Pharma’s Q2FY27 revenue grew 20.9% year over year, while EBITDA margin expanded to 37.2%. Specialty ingredients declined year over year.